Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 11, 2016, Pages 1638-1646.e2

  Goldberg, David ^a,b   French, Benjamin ^a,b   Newcomb, Craig ^b   Liu, Qing ^b   Sahota, Gurvaneet ^c   Wallace, Anna E ^c   Forde, Kimberly A ^a,b   Lewis, James D ^a,b   Halpern, Scott D ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HEALTHCORE INC   (United States)

Author keywords

Disparities; Liver Cancer; UNOS; Wait List

Indexed keywords

ADULT; AGED; ARTICLE; CALIFORNIA; COHORT ANALYSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; END STAGE LIVER DISEASE; FEMALE; FLORIDA; HOSPITAL MANAGEMENT; HUMAN; ICD-9; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAID; NEW YORK; OHIO; PATIENT CARE; PENNSYLVANIA; RETROSPECTIVE STUDY; WAIT LISTING; ADOLESCENT; CARCINOMA, HEPATOCELLULAR; HEALTH CARE DELIVERY; HOSPITAL ADMISSION; MIDDLE AGED; UNITED STATES;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; END STAGE LIVER DISEASE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; WAITING LISTS;

EID: 84994127985     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.06.019     Document Type: Article

References (27)

1. 1 Gentry, S.E., Massie, A.B., Cheek, S.W., et al. Addressing geographic disparities in liver transplantation through redistricting. Am J Transplant 13 (2013), 2052–2058.
2. 2 Goldberg, D.S., French, B., Sahota, G., et al. Use of population-based data to demonstrate how waitlist-based metrics overestimate geographic disparities in access to liver transplant care. Am J Transplant, 2016 [Epub ahead of print].
3. 3 Centers for Medicare and Medicaid Services. Medicaid Statistical Information System (MSIS) Tables. 2012. Available at: http://www.cms.gov/MedicaidDataSourcesGenInfo/MSIS/list.asp. Accessed April 4, 2012.
4. 4 Schelleman, H., Bilker, W.B., Strom, B.L., et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 127 (2011), 1102–1110.
5. 5 Platt, R., Wilson, M., Chan, K.A., et al. The new Sentinel Network: improving the evidence of medical-product safety. N Engl J Med 361 (2009), 645–647.
6. 6 Heimbach, J.K., Hirose, R., Stock, P.G., et al. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology 61 (2015), 1643–1650.
7. 7 Martin, P., DiMartini, A., Feng, S., et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 59 (2014), 1144–1165.
8. 8 Goldberg, D.S., Lewis, J.D., Halpern, S.D., et al. Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database. Pharmacoepidemiol Drug Saf 22 (2013), 103–107.
9. 9 Goldberg, D., Lewis, J., Halpern, S., et al. Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf 21 (2012), 765–769.
10. 10 Nehra, M.S., Ma, Y., Clark, C., et al. Use of administrative claims data for identifying patients with cirrhosis. J Clin Gastroenterol 47 (2013), e50–e54.
11. 11 Lo Re, V. 3rd, Lim, J.K., Goetz, M.B., et al. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf 20 (2011), 689–699.
12. 12 Kramer, J.R., Davila, J.A., Miller, E.D., et al. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther 27 (2008), 274–282.
13. 13 Setoguchi, S., Solomon, D.H., Glynn, R.J., et al. Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control 18 (2007), 561–569.
14. 14 Martin, P.D.A., Feng, S., Brown, R., et al. Evaluation for liver transplantation in adults: 2013 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 59 (2014), 1144–1165.
15. 15 Kim, W.R., Therneau, T.M., Benson, J.T., et al. Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology 43 (2006), 345–351.
16. 16 Jepsen, P., Vilstrup, H., Andersen, P.K., The clinical course of cirrhosis: the importance of multi-state models and competing risks analysis. Hepatology 62 (2014), 292–302.
17. 17 D'Amico, G., Garcia-Tsao, G., Pagliaro, L., Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44 (2006), 217–231.
18. 18 Volk, M.L., Hernandez, J.C., Lok, A.S., et al. Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl 13 (2007), 1515–1520.
19. 19 Health Resources and Services Administration Area Health Resources Files (AHRF). Available at: http://ahrf.hrsa.gov/. Accessed December 22, 2015.
20. 20 Carr, B.G., Branas, C.C., Metlay, J.P., et al. Access to emergency care in the United States. Ann Emerg Med 54 (2009), 261–269.
21. 21 Goldberg, D., French, B., Abt, P., et al. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma. Liver Transpl 18 (2012), 434–443.
22. 22 Berry, K., Ioannou, G.N., Comparison of liver transplant-related survival benefit in patients with vs without hepatocellular carcinoma in the United States. Gastroenterology 149 (2015), 669–680.
23. 23 Northup, P.G., Intagliata, N.M., Shah, N.L., et al. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation. Hepatology 61 (2015), 285–291.
24. 24 Schaubel, D.E., Guidinger, M.K., Biggins, S.W., et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant 9 (2009), 970–981.
25. 25 Merion, R.M., Schaubel, D.E., Dykstra, D.M., et al. The survival benefit of liver transplantation. Am J Transplant 5 (2005), 307–313.
26. 26 Julapalli, V.R., Kramer, J.R., El-Serag, H.B., Evaluation for liver transplantation: adherence to AASLD referral guidelines in a large Veterans Affairs center. Liver Transpl 11 (2005), 1370–1378.
27. 27 Goldberg, D., French, B., Thomasson, A., et al. Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era. Liver Transpl 17 (2011), 1355–1363.